title: Perivascular adipose tissue, potassium channels, and vascular dysfunction.
abstract: Perivascular adipose tissue has been recognized unequivocally as a major player in the pathology of metabolic and cardiovascular diseases. Through its production of adipokines and the release of other thus far unidentified factors, this recently discovered adipose tissue modulates vascular regulation and the myogenic response. After the discovery of its ability to diminish the vessel's response to vasoconstrictors, a new paradigm established adipose-derived relaxing factor (ADRF) as a paracrine smooth muscle cells' potassium channel opener that could potentially help combat vascular dysfunction. This review will discuss the role of ADRF in vascular dysfunction in obesity and hypertension, the different potassium channels that can be activated by this factor, and describes new pharmacological tools that can mimic the ADRF effect and thus can be beneficial against vascular dysfunction in cardiovascular disease.
authors.affiliation: From the Experimental and Clinical Research Center, Berlin-Buch, Germany; and Nephrology/Intensive Care Section, Charité Campus Virchow, Berlin, Germany. maik.gollasch@charite.de.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Tano
authors.affiliation: From the Experimental and Clinical Research Center, Berlin-Buch, Germany; and Nephrology/Intensive Care Section, Charité Campus Virchow, Berlin, Germany.
authors.forename: Johanna
authors.initials: J
authors.lastname: Schleifenbaum
authors.affiliation: From the Experimental and Clinical Research Center, Berlin-Buch, Germany; and Nephrology/Intensive Care Section, Charité Campus Virchow, Berlin, Germany.
authors.forename: Maik
authors.initials: M
authors.lastname: Gollasch
mesh_terms: D054392:Adipokines / Q000378:metabolism; D000273:Adipose Tissue / Q000473:pathology / Q000503:physiopathology*; D000818:Animals; D001685:Biological Factors / Q000502:physiology*; D001808:Blood Vessels / Q000473:pathology*; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000378:metabolism / Q000503:physiopathology; D051656:KCNQ Potassium Channels / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D054392:Adipokines; D001685:Biological Factors; D051656:KCNQ Potassium Channels; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D014662:Vasoconstrictor Agents
keywords: ADRF; KCNQ potassium channels; adipose tissue